Sugi Predict

Sugi Predict / Compounds / SCHEMBL353596

SCHEMBL353596

SCHEMBL353596

Cc1nc2ccc(Br)cc2o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ MAPT P10636 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ GAA P10253 2/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ TAS1R3 Q7RTX0 5/20 0.41
▸ TAS1R1 Q7RTX1 5/20 0.41
▸ ELANE P08246 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.40
▸ CHRNB2 P17787 1/20 0.39
▸ CHRNA4 P43681 1/20 0.39
▸ DAGLA Q9Y4D2 1/20 0.39
▸ MPO P05164 1/20 0.38
▸ CASP3 P42574 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1550272 0.84 RAB9A (0.59) POLBSMN1; SMN2KDM4EMAPTMEN1
SCHEMBL30190038 0.84 RAB9A (0.59) POLBSMN1; SMN2KDM4EMAPTMEN1
SCHEMBL5541680 0.79 KDM4E (0.63) POLBSMN1; SMN2KDM4EMAPTMEN1
SCHEMBL14330030 0.79 GAA (0.59) POLBSMN1; SMN2KDM4EMAPTMEN1
SCHEMBL31334714 0.76 DAGLA (0.42) NPC1RAB9ADAGLA
SCHEMBL30988526 0.76 PIK3CG (0.61) SMN1; SMN2KDM4EMAPTMEN1NPC1
SCHEMBL27629590 0.76 DAGLA (0.39) SMN1; SMN2KDM4EMAPTMEN1NPC1
SCHEMBL20552452 0.76 DAGLA (0.39) SMN1; SMN2KDM4EMAPTMEN1NPC1
SCHEMBL20552113 0.76 PIK3CG (0.43) KDM4EMAPTMEN1KMT2AALDH1A1
SCHEMBL7893733 0.76 PIK3CG (0.61) SMN1; SMN2KDM4EMAPTMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 — — US disclosed
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2025-11-25 — — US disclosed
EP-4539840-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Neuron23, Inc. (US) 2025-04-23 — — EP disclosed
CN-119730846-A Kinase modulators and methods of use thereof 神经元23公司 2025-03-28 — — CN disclosed
CN-119528903-A Compounds for the treatment of spinal muscular atrophy PTC医疗公司 2025-02-28 — — CN disclosed
CN-108299314-B Compounds for the treatment of spinal muscular atrophy PTC医疗公司 2024-11-26 — — CN disclosed
US-20240327393-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2024-10-03 — — US disclosed
WO-2024193640-A1 CDK INHIBITOR 上海齐鲁制药研究中心有限公司 2024-09-26 — — WO disclosed
WO-2023244788-A9 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-09-12 — — WO disclosed
CN-109988144-B Aromatic vinyl or aromatic ethyl derivative, preparation method, intermediate, pharmaceutical composition and application thereof 广州再极医药科技有限公司 2024-07-05 — — CN disclosed
US-20110263548-A1 PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-27 — — US disclosed
WO-2011074560-A1 OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY 塩野義製薬株式会社 (JP) 2011-06-23 — — WO disclosed
EP-2313395-A1 PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS Bristol-Myers Squibb Company (US) 2011-04-27 — — EP disclosed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 — — EP disclosed
WO-2010009183-A1 PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-21 — — WO disclosed
WO-2009135526-A1 ALPHA-MERCAPTO-AMIDES NOVARTIS AG (CH) 2009-11-12 — — WO disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 — — WO disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 — — US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 — — US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 POLB 1637/4885SMN1; SMN2 3985/4885KDM4E 4854/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 POLB 562/4885SMN1; SMN2 237/4885KDM4E 2036/4885
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DGKK, DGKG, DGKA POLB 1818/4885SMN1; SMN2 4657/4885KDM4E 1315/4885
US-20110263548-A1 PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS GPR119, GPR4, GPR3 POLB 4192/4885SMN1; SMN2 2854/4885KDM4E 3226/4885
US-20240327393-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF AIFM2, GPX1, GPX4 POLB 4036/4885SMN1; SMN2 1657/4885KDM4E 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.